Biofrontera (BFAGY)

Biofrontera AG operates as a biopharmaceutical company, which engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products are used for the treatment of chronic, antihistamine refractory urticaria and migraine prophylaxis. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Company profile

Ticker

BFAGY, BFAGY

Exchange

OTC

Website

biofrontera.com/

CEO

Hermann Luebbert

Incorporated

Germany

Location

Germany

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

SEC CIK

0001712641

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

BFAGY stock data

1M 1Y 5Y

Calendar

12 Apr 21

1 Jul 22

31 Dec 22

Financial summary

Financial statements Chart BFAGY financial data

Quarter (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Biofrontera earnings reports.

Institutional ownership, Q4 2021

BFAGY institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	2	7	-71.4%
Opened positions	0	0
Closed positions	5	0	NEW
Increased positions	1	2	-50.0%
Reduced positions	0	2	EXIT

13F shares	Current	Prev Q	Change
Total value	148.28M	188.63M	-21.4%
Total shares	30.39M	27.64M	+10.0%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Deutsche Balaton Aktiengesellschaft	16.99M	$62.52M	+19.7%
Maruho	13.4M	$85.76M	0.0%

Largest transactions	Shares	Bought/sold	Change
Deutsche Balaton Aktiengesellschaft	16.99M	+2.79M	+19.7%
MS Morgan Stanley	0	-14.3K	EXIT
1492 Capital Management	0	-12.61K	EXIT
Citadel Advisors	0	-10.72K	EXIT
UBS UBS Group AG - Registered Shares	0	-2.09K	EXIT
Advisor	0	-200	EXIT
Maruho	13.4M	0	0.0%
Proequities	0	0

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Dusa Pharmaceuticals

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AB, ACA, adult, al, albeit, alcohol, amicable, antimicrobial, arisen, ASP, Astaro, bactericidal, Baltic, bearer, Biden, Bilanzgewinn, biocolloid, biologist, blood, brightest, Bulletin, Bundesdatenschutzgesetz, businessman, CAGR, CCPA, Chicago, CJEU, compatibility, concomitant, counteract, dead, deadline, dealt, debate, departure, Dermatest, destination, DNA, dual, dynamic, Efudex, envisioned, epidermal, ethyl, fatal, felt, female, Finland, flagship, forestry, forty, Galenica, Gesetz, grace, gyrase, Haftung, Hanseatic, headcount, Heilmittelwerbegesetz, hinder, hygiene, IIb, immune, incomplete, incremental, influenced, Inline, Insight, Inspector, Interactive, Intershop, IQVIA, isolated, Joseph, Jr, keratinization, KPMG, Linkbase, lockdown, LTI, Ludwig, Lutter, malignant, Malm, mediate, men, middle, mir, missed, mortality, mupirocin, mutate, narrowband, Nordic, NVI, ODV, OIG, online, overturned, Oxford, pattern, payer, pediatric, pension, pharmacovigilance, PhD, pillar, plant, Poet, precautionary, precursor, predecessor, premature, prematurely, Privatbank, progression, proliferate, Quinolonecarboxylic, Quirin, radiation, reaction, reauthorization, reestimated, reevaluated, reintroduction, remote, reopened, Rescue, retransfer, retransferred, reversal, reverse, rewarding, RPI, Russian, Scandinavia, scenario, Schema, sending, sharp, sharply, shorten, Societal, soft, Stewardship, STI, strep, synthetic, Taxonomy, telehealth, tentatively, thatoverall, thrive, Tirbanibulin, top, topoisomerase, uncommon, underway, undiluted, unharmed, unified, unprecedented, unsure, unusual, uptake, urgent, UV, viability, vicinity, video, Vietnam, vitro, wake, Warsaw, wave, weaken, women, XBRL, xepi®, yellowish

Removed: accrue, acted, adapted, administer, advanced, aim, AktiengesellschaftorAG, Alacare®adhesive, Allergan, Ameluz®and, Ameluz®for, Ameluz®from, Ameluz®in, Ameluz®PDT, Ameluz®to, Ameluz®were, Ameluz®with, announcement, arranged, assuming, Belgium, belief, binominal, bioavailability, Biofrontera®figurative, bleed, blind, Bowen, capitalizing, carcinomain, Caucasian, centrally, CEO, CH, Chipcard, clinically, comfort, commented, concert, constituted, consultation, core, covalently, covenant, cycle, Dawson, deadly, decarboxylase, deeply, Delaware, demonstrating, depressing, depression, determinative, die, division, documented, downturn, DRAM, Dresden, dry, easier, emitted, excluded, explore, extra, familiar, fraction, front, function, globally, gram, grew, HaftungorGmbH, Hapila, hedge, Heptagon, highlight, histidine, histological, IFRIC, IL, immunosuppressed, inactive, incidence, includinginter, incorporate, individually, Infineon, infrared, ingenol, intent, intragroup, Israeli, itchy, journal, Kapital, Kerastick, keratotic, labeled, labelling, laboratory, Lake, Lang, laser, licensee, lodging, Luxembourg, Luxerm®cream, Luxerm®in, manuscript, marketplace, match, matched, mebutate, metabolism, Metvix®are, Metvix®in, moisturize, multicenter, multinational, negotiate, observation, occasion, opposite, orally, Oy, paragraph, penetrate, photosensitizing, pivotal, plaster, Portugal, prophylactic, prospectively, prototype, Qimonda, ranged, rapidly, rejected, rejuvenating, rejuvenation, relied, renew, renewal, repurchase, researched, rounded, scaly, screening, secondary, Semiconductor, sex, Solar, soothe, stability, stratification, subdivided, successive, supersede, survive, sustained, tablet, theproduct, therewith, thicker, tolerability, toxicology, tracked, train, tranchemultiplied, Ubidyne, unattractive, uncompetitive, underestimation, underwriting, unemployment, unstable, upper, urticaria, urticarial, Vector, warming, wherewithal, yield

From filing 20-F 2020 FY

Financial reports

20-F

2020 FY

Annual report (foreign)

12 Apr 21

20-F

2019 FY

Annual report (foreign)

21 Apr 20

20-F

2018 FY